Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02325 雲康集團
Listing Date2022/05/18
Listing Price7.890
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

Yunkang Group is a medical operation service provider in China offering a full suite of diagnostic testing services for medical institutions with a market share of 3.7% in China’s medical operation service market in terms of revenue in 2020.

Medical operation services primarily relate to diagnostic testing services provided to medical institutions which can be divided into diagnostic outsourcing services and diagnostic testing services for medical institution alliances. It provides such diagnostic testing services to medical institutions in its six independent clinical laboratories and on-site diagnostic centers in medical institutions. It also provides diagnostic testing services to non-medical institutions in China via an outpatient clinic.

Up to April 2022, the Group had assisted in establishing and operating 322 on-site diagnostic centers, serving over 700 medical institutions under its diagnostic testing services for medical institution alliances. Its customers primarily consisted of hospitals, community health clinics and non-medical institutions.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares138.19M shares
No. of International Offer Shares124.37M shares
No. of HK Offer Shares13.82M shares
Offer Price$7.89
Stock Code2325
Sponsor(s)CMB International Capital Limited, SPDB International Capital Limited
Underwriter(s)CMB International Capital Limited, SPDB International Capital Limited, China Merchants Securities (HK) Co., Limited, CCB International Capital Limited, CRIC Securities Company Limited, Futu Securities International (Hong Kong) Limited, Blackwell Global Securities Limited, Livermore Holdings Limited
Application PeriodMay 05 (Thu) - noon, May 11 (Wed)
Price Determination DateMay 11 (Wed)
Result Announcement DateOn or before May 17 (Tue)
Result Announcement DateOn or before May 17 (Tue)
Dealings in Shares commence onMay 18, 2022. (Wed)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$7.89
NAV / share ($)$4.18 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 7.89, the net proceeds raised would be HKD 760.90M, of which
55% : expanding and deepening medical institution alliance network over the next five years
20% : upgrading and enhancing operational capabilities and digitalize testing services
10% : expanding diagnostic capabilities with a focus on developing capabilities in key technologies
5% : potential investment and acquisition opportunities
5% : recruiting and training up talent pool
5% : working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.